Differences

This shows you the differences between two versions of the page.

--- covid-19_vaccines:lipid_nanoparticle [2022/03/03 02:14]
liam [Patents]
+++ covid-19_vaccines:lipid_nanoparticle [2022/11/24 19:45] (current)
liam [Intellectual Property and Patents]
@@ Line 13: / Line 13: @@
 ===== Intellectual Property and Patents =====
-The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial.
+The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial. See the below graphic from //Patent network analysis of mRNA-based vaccine candidates for COVID-19//:((Gaviria, M., & Kilic, B. (2021). //A network analysis of COVID-19 mRNA vaccine patents.// Nature Biotechnology, 39(5), 546–548. https://doi.org/10.1038/s41587-021-00912-9))
+{{:covid-19_vaccines:41587_2021_912_fig1_html_copy.jpg?600 |}}
 ==== Patents ====
@@ Line 25: / Line 27: @@
 The suit alleges that Moderna had licensed Arbutus' LNP technology for its products, but not specifically for their [[:moderna_mrna-1273|mRNA-1273]] [[:COVID-19 vaccines|COVID-19 vaccine product]]. While the companies are seeking financial compensation, they insist they do not intend to halt or otherwise impede the distribution of the product. Moderna denied the allegations, claiming they had created their own proprietary lipid nanoparticle delivery technology for use in their [[:mRNA]] platform.